The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| WGS | +123.02% | N/A | N/A | -61% |
| S&P | +16.23% | +94.45% | +14.22% | +96% |
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
It continued to ride high on its solid second-quarter performance.
There's nothing like a crushing double beat on quarterly results to give some life to a stock.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $102.69M | 45.6% |
| Gross Profit | $66.10M | 71.5% |
| Gross Margin | 64.37% | 9.7% |
| Market Cap | $2.63B | 285.3% |
| Market Cap / Employee | $2.63M | 0.0% |
| Employees | 1K | 0.0% |
| Net Income | $10.81M | 137.1% |
| EBITDA | $15.22M | 416.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $74.12M | 32.2% |
| Accounts Receivable | $48.03M | 88.3% |
| Inventory | 11.9 | 15.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $111.30M | -1.5% |
| Short Term Debt | $4.31M | -15.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.33% | 27.5% |
| Return On Invested Capital | -168.58% | 38.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $8.05M | 237.5% |
| Operating Free Cash Flow | $10.42M | 331.3% |
| Metric | Q2 2025 | YoY Change | |||
|---|---|---|---|---|---|
| Price to Earnings | 4936.36 | - | |||
| Price to Book | 5.89 | 10.31 | 10.12 | 10.23 | 210.49% |
| Price to Sales | 4.30 | 7.05 | 7.55 | 7.58 | 165.46% |
| Price to Tangible Book Value | 40.20 | 49.74 | 28.64 | 25.74 | 43.62% |
| Price to Free Cash Flow TTM | 3309.14 | - | |||
| Enterprise Value to EBITDA | -973.60 | 145.30 | 1453.90 | 179.17 | -221.97% |
| Free Cash Flow Yield | 0.0% | - | |||
| Return on Equity | -36.4% | -22.1% | -16.6% | 0.6% | -101.25% |
| Total Debt | $117.31M | $117.38M | $116.05M | $115.61M | -2.08% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
